These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 20932288)

  • 1. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?
    Langer A
    BMC Health Serv Res; 2010 Oct; 10():283. PubMed ID: 20932288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
    Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
    Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
    Facey K; Bradbury I; Laking G; Payne E
    Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling.
    Meads C; Auguste P; Davenport C; Małysiak S; Sundar S; Kowalska M; Zapalska A; Guest P; Thangaratinam S; Martin-Hirsch P; Borowiack E; Barton P; Roberts T; Khan K
    Health Technol Assess; 2013 Mar; 17(12):1-323. PubMed ID: 23537558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
    Auguste P; Barton P; Hyde C; Roberts TE
    Health Technol Assess; 2011 Apr; 15(18):iii-iv, 1-54. PubMed ID: 21524363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.
    Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM
    Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation.
    Cooper KL; Meng Y; Harnan S; Ward SE; Fitzgerald P; Papaioannou D; Wyld L; Ingram C; Wilkinson ID; Lorenz E
    Health Technol Assess; 2011 Jan; 15(4):iii-iv, 1-134. PubMed ID: 21276372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
    Buck AK; Herrmann K; Stargardt T; Dechow T; Krause BJ; Schreyögg J
    J Nucl Med Technol; 2010 Mar; 38(1):6-17. PubMed ID: 20197541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(16):1-167. PubMed ID: 23074467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
    Buck AK; Herrmann K; Stargardt T; Dechow T; Krause BJ; Schreyögg J
    J Nucl Med; 2010 Mar; 51(3):401-12. PubMed ID: 20150250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation.
    Duarte A; Corbett M; Melton H; Harden M; Palmer S; Soares M; Simmonds M
    Health Technol Assess; 2022 Dec; 26(49):1-184. PubMed ID: 36534989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of PET and PET/computed tomography: a systematic review.
    Gerke O; Hermansson R; Hess S; Schifter S; Vach W; Høilund-Carlsen PF
    PET Clin; 2015 Jan; 10(1):105-24. PubMed ID: 25455883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
    Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating PET-CT in routine surveillance and follow-up after treatment for cervical cancer: a cost-effectiveness analysis.
    Auguste P; Barton P; Meads C; Davenport C; Małysiak S; Kowalska M; Zapalska A; Guest P; Martin-Hirsch P; Borowiack E; Khan K; Sundar S; Roberts T
    BJOG; 2014 Mar; 121(4):464-76. PubMed ID: 24299112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
    Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
    J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
    Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
    Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.